Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

BACKGROUND: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque‐type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE: To demonstrate equivalent efficacy and comparable safety and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerdes, S., Thaçi, D., Griffiths, C.E.M., Arenberger, P., Poetzl, J., Wuerth, G., Afonso, M., Woehling, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887937/
https://www.ncbi.nlm.nih.gov/pubmed/28960486
http://dx.doi.org/10.1111/jdv.14605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887937/
https://www.ncbi.nlm.nih.gov/pubmed/28960486
http://dx.doi.org/10.1111/jdv.14605

Ejemplares similares